1stOncology™: Cancer Intelligence Service – Page 11126 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index

On December 18, 2020 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: ^NBI), effective prior to market open on Monday, December 21, 2020 (Press release, Syndax, DEC 18, 2020, View Source [SID1234573040]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The NASDAQ Biotechnology Index was launched in 1993 and is designed to track the performance of a set of securities listed on the NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including an average daily trading volume, minimum market capitalization, and other criteria. The index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit View Source

MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule

On December 18, 2020 MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc (Press release, MacroGenics, DEC 18, 2020, View Source [SID1234573039]). The research collaboration will incorporate MacroGenics’ proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.

"We are excited to collaborate with Janssen, which we believe is a leader in the field of next generation antibody-based therapeutics, by bringing together our two companies’ respective scientific talent and experience to leverage our DART platform to generate a compelling product candidate that addresses unmet patient needs," said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics.

Under the terms of the agreement, Janssen will pay MacroGenics an upfront payment of $20 million and will be responsible for funding all expenses. MacroGenics will also be eligible to receive up to $312 million in potential milestone payments and tiered royalties on worldwide product sales. Further details about the transaction are not disclosed.

Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock

On December 18, 2020 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, reported the pricing of an upsized underwritten public offering with gross proceeds to the Company expected to be approximately $26.4 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company (Press release, Greenwich LifeSciences, DEC 18, 2020, View Source [SID1234573038]).

The public offering equates to 660,000 shares of the Company’s common stock at a price of $40.00 per share. The Company intends to use the net proceeds for completion of all manufacturing and all clinical trial activities to complete an interim analysis and data readout of the GP2 Phase III clinical trial, for the submission of a Biologics Licensing Application to the FDA seeking conditional marketing approval of GP2, for the in-licensing or acquisition and development of additional products, including the coronavirus vaccine program, and for working capital and general corporate purposes.

The Company has also granted the underwriters a 45-day option to purchase up to an additional 99,000 shares of common stock offered in the public offering to cover over-allotments, if any, at the public offering price, which would increase the total gross proceeds of the offering to approximately $30.4 million, if exercised in full. The offering is expected to close on or about December 22, 2020, subject to customary closing conditions.

Aegis Capital Corp. is acting as sole bookrunner for the offering.

A registration statement relating to the shares of common stock being sold in this offering was declared effective by the Securities and Exchange Commission (the "SEC") on December 17, 2020. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, on the SEC’s website, www.sec.gov, or by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at [email protected], or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Mersana Therapeutics to Host Virtual Analyst and Investor Event

On December 17, 2020 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that it will host a virtual Analyst and Investor event on Tuesday, January 5, 2021 from 10:00 a.m. to 12:00 p.m. ET (Press release, Mersana Therapeutics, DEC 17, 2020, View Source [SID1234575006]). The event will showcase the following agenda:

Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecologic Oncology at the OU Health Stephenson Cancer Center and the Sarah Cannon Research Institute, will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company’s first-in-class ADC candidate targeting NaPi2b.
Mersana’s management team will detail the Company’s plans for the registration-enabling study of XMT-1536 in platinum-resistant ovarian cancer and outline its objectives for longer-term life cycle management studies to evaluate the potential of XMT-1536 in platinum-sensitive ovarian cancer.
Mersana’s management team will disclose preclinical data supporting the development of the Company’s first-in-class B7-H4 DolaLock ADC development candidate.
Mersana’s management team will outline the Company’s anticipated 2021 goals and milestones for its clinical and early-stage ADC programs.
Webcast and Conference Call Details
A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at View Source Analyst and Investors may ask a question during the live Q&A by dialing (855) 940-5308 (toll-free domestic) or (929) 517-9745 (international) and providing the Conference ID 6265117.

Perrigo to Present Virtually at Upcoming Investor Conferences

On December 17, 2020 Perrigo Company plc (NYSE; TASE: PRGO), reported that EVP and President of Consumer Self-Care Americas, Rich Sorota will present at the ICR Conference at 11:30 AM EST on Monday, January 11, 2021 (Press release, Perrigo Company, DEC 17, 2020, View Source [SID1234573012]).

Perrigo President & CEO Murray S. Kessler and CFO, Ray Silcock, will present at the 39th Annual J.P. Morgan Global Healthcare Conference at 3:40 PM EST on Wednesday, January 13, 2021. Interested parties can access the presentation webcasts at View Source